Quantum binding energy features of the drug olmesartan bounded to angiotensin type-1 receptor in the therapeutics of stroke

2021 ◽  
Author(s):  
Stephany Campanelli Esmaile ◽  
Daniel Melo de Oliveira Campos ◽  
Maria Karolaynne da Silva ◽  
Katyanna Sales Bezerra ◽  
J. X. Lima Neto ◽  
...  

Stroke is the second most common cause of mortality worldwide and the third most common cause of disability. Stroke causes and hemodynamic consequences are heterogeneous, making blood pressure management in...

2021 ◽  
pp. 0271678X2110043
Author(s):  
Thompson G Robinson ◽  
Jatinder S Minhas ◽  
Joseph Miller

Over the last two decades, there have been a number of major landmark clinical trials, classified as “major” as they sought to address clear clinical practice driven questions, in a pragmatic yet robust trial design, using a large powered sample size (n > 1000), in order to help improve patient outcome through informing guidelines. A commonality across all stroke sub-types included in these trials is the tendency to acute hypertensive crises within the acute stroke period. This phenomenon is associated with greater stroke complications and worsened overall prognosis. Multiple trials have attempted to address the issue of acute blood pressure management during the acute stroke period, with consideration for timing, magnitude of lowering, agent and relationship to other interventions. This review will consider the major clinical trials performed in ischaemic and haemorrhagic stroke that test the hypothesis that acute BP reduction improves clinical outcomes.


Stroke ◽  
2012 ◽  
Vol 43 (2) ◽  
pp. 557-559 ◽  
Author(s):  
Erin McDonough Grise ◽  
Opeolu Adeoye ◽  
Christopher Lindsell ◽  
Kathleen Alwell ◽  
Charles Moomaw ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document